Literature DB >> 21450523

Population-based investigation of fluoroquinolones resistant tuberculosis in rural eastern China.

Yi Hu1, Barun Mathema, Weibing Wang, Barry Kreiswirth, Weili Jiang, Biao Xu.   

Abstract

Empirical use of fluoroquinolones (FQ) to treat a variety of bacterial infections may inadvertently select for FQ-resistant strains of Mycobacterium tuberculosis(MTB), especially in rural China where the use of FQ in treating infections has not been standardized. Here we determine the prevalence and describe the transmission of FQ-resistant MTB in two rural counties in eastern China through a combination of conventional epidemiology with IS6110-based restriction fragment length polymorphism(RFLP) analysis and DNA sequencing of drug-resistance determining regions. Phenotypic FQ resistance was detected in 31 of 351(8.8%) isolates. FQ resistance was equally distributed between patient-isolates deemed drug resistant and drug-susceptible, but mostly observed in those with treatment history of respiratory infection. Mutations in gyrA were found in 54.8% of FQ resistant isolates, and one isolate with a gyrB mutation. Despite predominating in entire bacilli population(69.2%), Beijing family strain had similar proportion of FQ resistance to the other(10.3% vs. 4.7%, p = 0.060). IS6110RFLP identified 2 clusters(4 isolates) among FQ resistant isolates and 3 clusters composed of both 4 FQ resistant isolates and 6 FQ susceptible isolates. Our results indicate that FQ-resistant MTB has emerged among the circulating bacillary population in rural eastern China. The relatively low level of clustering among FQ-resistant strains suggests most are acquired de novo, likely due to widespread FQ use.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21450523     DOI: 10.1016/j.tube.2011.03.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  7 in total

Review 1.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

2.  Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant Mycobacterium aurum.

Authors:  Rui Pi; Qingyun Liu; Howard E Takiff; Qian Gao
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

3.  High-resolution melting analysis for the rapid detection of fluoroquinolone and streptomycin resistance in Mycobacterium tuberculosis.

Authors:  Ann S G Lee; Danny C T Ong; Joshua C L Wong; Gilman K H Siu; Wing-Cheong Yam
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

4.  New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations.

Authors:  Seidu Malik; Melisa Willby; David Sikes; Oleg V Tsodikov; James E Posey
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

Review 5.  Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.

Authors:  Elisea Avalos; Donald Catanzaro; Antonino Catanzaro; Theodore Ganiats; Stephanie Brodine; John Alcaraz; Timothy Rodwell
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

6.  Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study.

Authors:  Yangyi Zhang; Yuan Jiang; Chenlei Yu; Jing Li; Xuhui Shen; Qichao Pan; Xin Shen
Journal:  Front Public Health       Date:  2022-09-15

7.  Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.

Authors:  L Rigouts; N Coeck; M Gumusboga; W B de Rijk; K J M Aung; M A Hossain; K Fissette; H L Rieder; C J Meehan; B C de Jong; A Van Deun
Journal:  J Antimicrob Chemother       Date:  2015-11-24       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.